Literature DB >> 2566669

Sulfasalazine-induced hepatotoxicity in children with inflammatory bowel disease.

D L Boyer1, B U Li, J N Fyda, R A Friedman.   

Abstract

A case of severe sulfasalazine-induced hepatotoxicity is reported in a 14-year-old girl with Crohn's disease. Fourteen days after beginning sulfasalazine, she developed a systemic reaction characterized by high fever, maculopapular rash, lymphadenopathy, abdominal pain, and malaise, with tender hepatomegaly and elevated liver functions, leukemoid reaction, with eosinophilia, and immune complexes. She responded promptly to high-dose intravenous steroids with complete recovery. This case was compared to the three similar pediatric cases in the literature. The latent period was 11-19 days between sulfasalazine therapy and the onset of high fever, generalized lymphadenopathy, and pruritic maculopapular rash that spared palms and soles and resolved with desquamation. All children had hepatotoxicity indicated by tender hepatomegaly, elevated liver enzymes, and histologic inflammation on liver biopsy. The similarity between these features and those of other sulfa-induced hepatotoxic reactions suggests that the sulfapyridine moiety is the etiologic agent in these hypersensitivity reactions. Those children with circulating immune complexes responded well to steroids. Proper therapy for this rare but severe idiosyncratic reaction includes prompt recognition and discontinuation of sulfasalazine, and high-dose corticosteroid therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2566669     DOI: 10.1097/00005176-198905000-00018

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  7 in total

Review 1.  Current therapy of inflammatory bowel disease in children.

Authors:  Paul A Rufo; Athos Bousvaros
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

2.  The natural plant product sophocarpine ameliorates dextran sodium sulfate-induced colitis in mice by regulating cytokine balance.

Authors:  Xiao-juan Wang; Hong-zhu Deng; Bin Jiang; Hui Yao
Journal:  Int J Colorectal Dis       Date:  2011-11-15       Impact factor: 2.571

3.  Sulphasalazine induced hepatitis in juvenile rheumatoid arthritis.

Authors:  D Caspi; D Fuchs; M Yaron
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

Review 4.  Hepatic manifestations of non-steroidal inflammatory bowel disease therapy.

Authors:  Robert Hirten; Keith Sultan; Ashby Thomas; David E Bernstein
Journal:  World J Hepatol       Date:  2015-11-28

Review 5.  Hepatobiliary manifestations of inflammatory bowel disease in children.

Authors:  Magdalena Kucharska; Urszula Daniluk; Kamila Agnieszka Kwiatek-Średzińska; Natalia Wasilewska; Aleksandra Filimoniuk; Piotr Jakimiec; Katarzyna Zdanowicz; Dariusz Marek Lebensztejn
Journal:  Clin Exp Hepatol       Date:  2019-09-05

6.  Effect of Thiol-reducing Agents and Antioxidants on Sulfasalazine-induced Hepatic Injury in Normotermic Recirculating Isolated Perfused Rat Liver.

Authors:  Reza Heidari; Neda Esmailie; Negar Azarpira; Asma Najibi; Hossein Niknahad
Journal:  Toxicol Res       Date:  2016-04-30

7.  Sulfasalazine-induced renal and hepatic injury in rats and the protective role of taurine.

Authors:  Reza Heidari; Maryam Rasti; Babak Shirazi Yeganeh; Hossein Niknahad; Arastoo Saeedi; Asma Najibi
Journal:  Bioimpacts       Date:  2016-03-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.